2014-02-17 04:10:01 – Physician Views: Do EU Pulmonologists Anticipate Rapid Uptake for GSKâs Seretide-Successor? – a new market research report on companiesandmarkets.com
This week´s Physician Views poll will specifically ask pulmonologists based in the 5EU countries:
– What percentage of COPD patients they currently treat with twice-daily (BID) LABA/ICS combination therapies?
– What percentage of these patients fail to comply with BID dosing?
– What percentage of patients treated with Seretide they expect to switch to Relvar Ellipta based on its once-daily (QD) dosing profile?
– Their assessment of the efficacy benefit provided by Relvar Ellipta over Seretide
– How restrictive they expect payers to act towards Relvar Ellipta given that its QD dosing profile is likely to be perceived as its primary form of differentiation versus Seretide
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and
Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.